Directa Plus shares slide 23% as cash falls and funding needs loom

Directa Plus expects FY revenue of €7.0m (vs €6.66m prior) and an adjusted EBITDA loss of about €2.5m, an approximate 30% improvement year‑on‑year, but gross cash plunged to €1.5m from nearly €5.0m a year earlier, triggering a 23% share drop to 10.44p. Management says it will seek funding solutions for 2026 while exploring IP monetisation and partnerships; operational moves at Setcar delivered at least €0.7m annualised savings and a €1.5m waste contract with Ford, and long‑serving chairman Richard Hickinbotham will step down at end‑January.

Analysis

Market structure: The immediate winners are well‑capitalized diversified chemicals/advanced‑materials groups and OEMs (e.g., Ford) that can internalize graphene development or pick up IP via licensing; losers are small pure‑play graphene AIM names (Directa DCTA) and holders of illiquid microcaps as risk premia reprice. Funding weakness materially reduces Directa’s commercialization pace, shifting near‑term share and pricing power to larger incumbents and potential licensees; rising AIM small‑cap vol and credit spreads are likely, and EUR funding needs create FX sensitivity if raises priced in GBP or USD.

Risk assessment: Tail risks include a failed 2026 fundraising leading to equity wipeout or administration, cancellation or re‑negotiation of the not‑fully‑formalised €1.5m Ford deal, and IP litigation/standards/regulatory setback; these are low probability but can remove >100% equity value. Time horizons: days — elevated volatility and potential placement rumors; weeks/months — fundraising/board change and Ford term finalisation; quarters/years — monetisation of IP via licensing/JVs. Hidden dependency: Setcar’s €1.5m contract and €0.7m annualised savings represent a large share of near‑term cash generation and materially affect runway.

Trade implications: Tactical short DCTA is justified until funding clarity; consider a small 1–2% portfolio short with tight risk controls (see decisions). Conversely, a conditional long if Directa secures non‑dilutive funding ≥€3.5–4.0m or announces a licensing/JV within 60–90 days, as that would re‑rate IP; larger durable exposure belongs in large cap chemicals (BAS.DE / LON:JMAT) not microcaps. Options: buy puts or put spreads on DCTA only if liquid IV rises >30% to cost‑effectively cap downside; otherwise use equity shorts plus index protection.

Contrarian angles: The market may be overlooking tangible revenue growth (FY rev ~€7m, adj EBITDA loss improving ~30%) and concrete cost savings (€0.7m) which reduce the amount of dilution required; historical parallels show subscale materials plays often bounce 50–200% on a licensing/JV announcement. Reaction could be overdone if management secures non‑dilutive partners or finalises the Ford contract—these are binary catalysts that would quickly compress implied volatility and force short covering.

Key Decisions for Investors

• Establish a tactical short position in Directa Plus (AIM:DCTA / OTC:DTPKF) sized 1–2% of portfolio at or below current market ~10.5p; set a stop‑loss at 14p and a profit target near 6p, horizon 3 months. Rationale: cash runway (€1.5m) implies high probability of dilutive financing absent non‑dilutive deal within 60–90 days.
• Prepare a conditional long allocation (2–3% position) to DCTA that will be executed only if the company announces non‑dilutive funding ≥€3.5–4.0m or a licensing/JV agreement by 31 March 2026; initial target +40–70% upside and hard stop −25% from entry. Rationale: material de‑risking events would rapidly re‑rate IP value.
• Reduce exposure to AIM/small‑cap specialty materials by 2–4% and redeploy into large‑cap diversified chemical/advanced materials (example tickers: BAS.DE (BASF) or LON:JMAT (Johnson Matthey)) with a 6–12 month horizon to capture stable margins and lower refinancing risk.
• If Directa discloses gross cash falling below €1.0m in the next 60 days or announces an equity raise priced below 8p, increase short exposure to 3% and buy 3‑month put protection on a UK small‑cap materials basket (or use FTSE‑250 put) to hedge cluster risk; conversely, if IV on DCTA rises >30% and options are tradable, buy a 3‑month put spread to cap downside economically.